Stockreport

Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic [Read more]